Concepedia

Steve Alas

SA

6

Publications

1.4K

Citations

6

H-Index

1997

Active since

Affiliations

University of California, Los Angeles(Current)

Steve Alas is an author at University of California, Los Angeles specializing in immunotherapy, immunology, and cell biology.

Top concepts

MedicineCell DeathImmunologyCell BiologyImmunotherapyTumor MicroenvironmentAutoimmunityCell SignalingRadiation OncologyOncology

Publications per year

1997–2003

6

Publications

6

Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

Aïcha Demidem, Tammy Lam, Steve Alas et al. · Cancer Biotherapy and Radiopharmaceuticals · 1997 · 397 citations

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

Steve Alas, Benjamin Bonavida · PubMed · 2001 · 295 citations

Il-10 Expression, Immunology, Cell Death +18

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Steve Alas, Christos Emmanouilides, Benjamin Bonavida · PubMed · 2001 · 281 citations

Lymphoid Neoplasia, Il-10 Levels, Immune Regulation +15

Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

Steve Alas, Benjamin Bonavida · PubMed · 2003 · 241 citations

Apoptosis, Immunology, Cell Death +20

Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.

Steve Alas, Chuen‐Pei Ng, Benjamin Bonavida · PubMed · 2002 · 89 citations

Rows per page

1–5 of 6